Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833831 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT02833831: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT02833831 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 103 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02833831, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of supratherapeutic exposures of ALS-008176 on the QT/ corrected QT interval (QTc) interval in healthy participants (Panel 2).
Primary Outcome
Change from baseline in QTc intervals with Fredericia correction will be analyzed.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG ALS-008176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-06-02 |
| Est. Completion | 2017-02-24 |
| Phase | Phase 1 |
What the finished NCT02833831 record still lists
NCT02833831 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02833831 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02833831 about?
NCT02833831 is a clinical study titled "Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants". The primary objective of this study is to evaluate the effect of supratherapeutic exposures of ALS-008176 on the QT/ corrected QT interval (QTc) interval in healthy participants (Panel 2).
What is the current status of trial NCT02833831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2016-06-02. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT02833831?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), ALS-008176 (DRUG).
Who is sponsoring clinical trial NCT02833831?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02833831's enrollment target sits among peer trials
103 541st of 2000 higher than 1,458 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI